A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States
| Status: | Archived |
|---|---|
| Conditions: | HIV / AIDS |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | June 2009 |
| End Date: | April 2010 |
A Double-blind, Randomized, Placebo-controlled Phase I/II Trial to Evaluate the Safety of Dapivirine Gel, 0.05%, 2.5g and Dapivirine Gel 2759, 0.05%, 2.5g Formulations as Compared to the Vaginal HEC-based Universal Placebo Gel, 2.5g in Healthy, HIV-negative Women.
IPM 020 is a double-blind, randomized, placebo-controlled Phase I/II expanded safety trial
being conducted at 5 research centers in the United States among approximately 180 healthy,
sexually active, HIV-negative women to assess the safety of Dapivirine Gel 4759, 0.05% 2.5g
and Dapivirine Gel 4789, 0.05% 2.5g as compared to the HEC-based universal placebo.
We found this trial at
5
sites
Albert Einstein College of Medicine The Albert Einstein College of Medicine of Yeshiva University is...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials